drugset / Trial / NCT06026514
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
Phase 1
Completed
27 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Johns Hopkins Bloomberg School of Public Health · collabNational Institutes of Health (NIH) · collab
NaSequentialOpen-labelPrevention
Summary
This Phase 1 clinical trial will evaluate the safety and immunogenicity of an intranasal vaccine candidate, a recombinant, live-attenuated, bovine/human parainfluenza virus vector vaccine expressing the 6-P prefusion-stabilized version of the SARS-CoV-2 spike protein.
Timeline
- Start
- 2023-09-18
- Primary completion
- 2025-01-16
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rB/HPIV3 | Vaccine | — | Intranasal |